Stay updated with breaking news from Replimune group. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Replimune Group (NASDAQ:REPL) & PharmaCyte Biotech (OTCMKTS:PMCBD) Critical Comparison etfdailynews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from etfdailynews.com Daily Mail and Mail on Sunday newspapers.
The combination of RP1 and cemiplimab provided a numerical, but not statistically significant, improvement in response rates vs cemiplimab alone in patients with locally advanced or metastatic cutaneous squamous cell carcinoma, missing the primary end points of the phase 2 CERPASS trial.
Replimune Group (NASDAQ:REPL – Free Report) had its target price decreased by Barclays from $50.00 to $13.00 in a research report report published on Wednesday morning, Benzinga reports. Barclays currently has an overweight rating on the stock. A number of other brokerages also recently weighed in on REPL. Wedbush reaffirmed an outperform rating and issued […]
Camber Capital Management LP increased its holdings in shares of Replimune Group, Inc. (NASDAQ:REPL – Free Report) by 24.0% during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 1,550,000 shares of the company’s stock after acquiring an additional 300,000 shares […]
Caption Management LLC purchased a new stake in Replimune Group, Inc. (NASDAQ:REPL – Free Report) in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor purchased 32,968 shares of the company’s stock, valued at approximately $766,000. Caption Management LLC owned approximately 0.06% […]
-- Health care stocks were slipping late Tuesday afternoon with the NYSE Health Care Index down 0.4% and the Health Care Select Sector SPDR Fund off 0.1%. The iShares Biotechnology ETF dropped...
Mirae Asset Global Investments Co. Ltd. boosted its stake in Replimune Group, Inc. (NASDAQ:REPL – Free Report) by 6.0% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 29,226 shares of the company’s stock after purchasing an additional 1,649 shares […]
Replimune Group said on Tuesday its experimental combination therapy to treat a common form of skin cancer failed to significantly remove or reduce cancerous lesions in a midstage study.